Biotech | January 12, 2022
ABL Bio collaborates with SANOFI for Parkinson’s antibody
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
